SCHEMBL6574038

SCHEMBL6574038

Cc1cc(COC(=O)Nc2ccccc2)c(C)cc1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
LMNA P02545 3/20 0.47
MAPT P10636 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47
HTT P42858 1/20 0.46
MGLL Q99685 1/20 0.46
HPGD P15428 2/20 0.45
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45
POLB P06746 1/20 0.45
TDP1 Q9NUW8 2/20 0.44
ALDH1A1 P00352 4/20 0.44
TSHR P16473 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ALOX15 P16050 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MEN1 O00255 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6570580 0.80 NPC1 (0.47) NPC1RAB9ALMNAMAPTSMN1; SMN2
SCHEMBL4201821 0.76 NPC1 (0.66) NPC1RAB9AMAPTSMN1; SMN2MGLL
SCHEMBL12325529 0.76 MGLL (0.59) NPC1RAB9AMAPTSMN1; SMN2MGLL
SCHEMBL6574035 0.75 ALDH1A1 (0.60) NPC1RAB9ASMN1; SMN2MAPK1HSD17B10
SCHEMBL8442974 0.73 NPC1 (0.51) NPC1RAB9ALMNAMAPTSMN1; SMN2
SCHEMBL6765228 0.73 SMN1; SMN2 (0.48) NPC1RAB9ALMNAMAPTSMN1; SMN2
Ethyl Phenylcarbamate SCHEMBL264865 0.72 RAB9A (0.75) NPC1RAB9ALMNAMAPTSMN1; SMN2
Ethyl Phenylcarbamate SCHEMBL11593824 0.72 RAB9A (0.75) NPC1RAB9ALMNAMAPTSMN1; SMN2
Ethyl Phenylcarbamate SCHEMBL11373641 0.72 RAB9A (0.65) NPC1RAB9ALMNAMAPTSMN1; SMN2
SCHEMBL1336033 0.71 POLB (0.60) NPC1RAB9ALMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040248897-A1 Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-12-09 US disclosed
EP-1414790-A1 SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-05-06 EP disclosed
WO-2003000653-A1 SUBSTITUTED N-ACYL ANILINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248897-A1 Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions NAT1, CYP3A5, CYP3A7 NPC1 1387/4885RAB9A 1413/4885LMNA 1447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.